Pharma Equity Group A/S's latest marketcap:
As of 07/26/2025, Pharma Equity Group A/S's market capitalization has reached $23.18 M. According to our data, Pharma Equity Group A/S is the 35535th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 23.18 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -3,842,232.78 |
| Shares Out | 1.23 B |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/14/2025 |
Pharma Equity Group A/S's yearly market capitalization.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/26/2025 | kr147.31 M | $23.18 M | -36.84% | 35535 |
| 12/30/2024 | kr233.24 M | $32.26 M | -46.98% | 31002 |
| 12/29/2023 | kr439.87 M | $65.11 M | 26006 |
Company Profile
About Pharma Equity Group A/S
Pharma Equity Group A/S is a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with significant patient and social impact. The company operates through its subsidiary, Reponex Pharmaceuticals A/S, and targets conditions where current therapies are inadequate or require improvement.
Key Products in Development
- RNX-011 – Phase II clinical trials for bacterial peritonitis.
- RNX-021, RNX-022, RNX-023 – Phase II trials for chronic skin ulcers.
- RNX-041 – Phase II trials for inflammatory bowel diseases (e.g., Crohn's and pouchitis).
- RNX-051 – Phase II trials for colorectal cancer and colon adenoma.
Founded in 2002, Pharma Equity Group A/S is headquartered in Horsholm, Denmark.
Frequently Asked Questions
-
What is Pharma Equity Group A/S's (CPH-PEG) current market cap?As of 07/26/2025, Pharma Equity Group A/S (including the parent company, if applicable) has an estimated market capitalization of $23.18 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Pharma Equity Group A/S (CPH-PEG) rank globally by market cap?Pharma Equity Group A/S global market capitalization ranking is approximately 35535 as of 07/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.